GE HealthCare Technologies (GEHC) 51st Nasdaq London Investor Conference summary

Strategic direction and innovation

• Confirmed and improved midterm outlook with mid-single digit sales growth and margin expansion to high teens or above 20% over the next several years.

• Focused on innovation in pharmaceutical diagnostics, especially radiopharmaceuticals and contrast media, with continued investment in supply security and new product launches.

• Highlighted Flyrcado, a next-generation PET imaging agent for cardiac diagnostics, targeting over $500 million in revenue by 2028.

• Emphasized the advantage of integrating diagnostic pharmaceuticals with imaging equipment to offer comprehensive solutions for hospitals.

• Eight new assets are under development in the product pipeline, signaling robust future growth.

Market environment and geographic trends

• U.S. hospital investment remains strong, with 8% sales growth and robust order growth in the latest quarter.

• China market outlook remains uncertain due to macroeconomic, anti-corruption, and stimulus factors, with muted impact expected in the first half of next year.

• China has historically been volatile but remains a long-term growth catalyst.

Product and reimbursement developments

• Recent U.S. reimbursement changes unbundle payments for PET scans and diagnostic pharmaceuticals, improving hospital economics and encouraging adoption of advanced diagnostics.

• Anticipated shift from invasive, lower-cost procedures to higher-quality, non-invasive diagnostics, especially in Alzheimer's imaging.

• Controlled launch of Flyrcado planned for end of Q1 next year, with expansion tied to PET installed base and infrastructure build-out.